Literature DB >> 32939786

Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis.

Nadim Mahmud1,2, Zachary Fricker3, Rebecca A Hubbard4, George N Ioannou5,6, James D Lewis1,2, Tamar H Taddei7,8, Kenneth D Rothstein1, Marina Serper1,9, David S Goldberg10, David E Kaplan1,9.   

Abstract

BACKGROUND AND AIMS: Patients with cirrhosis are at increased risk of postoperative mortality. Currently available tools to predict postoperative risk are suboptimally calibrated and do not account for surgery type. Our objective was to use population-level data to derive and internally validate cirrhosis surgical risk models. APPROACH AND
RESULTS: We conducted a retrospective cohort study using data from the Veterans Outcomes and Costs Associated with Liver Disease (VOCAL) cohort, which contains granular data on patients with cirrhosis from 128 U.S. medical centers, merged with the Veterans Affairs Surgical Quality Improvement Program (VASQIP) to identify surgical procedures. We categorized surgeries as abdominal wall, vascular, abdominal, cardiac, chest, or orthopedic and used multivariable logistic regression to model 30-, 90-, and 180-day postoperative mortality (VOCAL-Penn models). We compared model discrimination and calibration of VOCAL-Penn to the Mayo Risk Score (MRS), Model for End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease-Sodium MELD-Na, and Child-Turcotte-Pugh (CTP) scores. We identified 4,712 surgical procedures in 3,785 patients with cirrhosis. The VOCAL-Penn models were derived and internally validated with excellent discrimination (30-day postoperative mortality C-statistic = 0.859; 95% confidence interval [CI], 0.809-0.909). Predictors included age, preoperative albumin, platelet count, bilirubin, surgery category, emergency indication, fatty liver disease, American Society of Anesthesiologists classification, and obesity. Model performance was superior to MELD, MELD-Na, CTP, and MRS at all time points (e.g., 30-day postoperative mortality C-statistic for MRS = 0.766; 95% CI, 0.676-0.855) in terms of discrimination and calibration.
CONCLUSIONS: The VOCAL-Penn models substantially improve postoperative mortality predictions in patients with cirrhosis. These models may be applied in practice to improve preoperative risk stratification and optimize patient selection for surgical procedures (www.vocalpennscore.com).
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32939786      PMCID: PMC7902392          DOI: 10.1002/hep.31558

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

1.  Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data.

Authors:  N Husain; P Blais; J Kramer; M Kowalkowski; P Richardson; H B El-Serag; F Kanwal
Journal:  Aliment Pharmacol Ther       Date:  2014-08-26       Impact factor: 8.171

2.  Umbilical herniorrhapy in cirrhosis: improved outcomes with elective repair.

Authors:  Stephen H Gray; Catherine C Vick; Laura A Graham; Kelly R Finan; Leigh A Neumayer; Mary T Hawn
Journal:  J Gastrointest Surg       Date:  2008-04       Impact factor: 3.452

Review 3.  AGA Clinical Practice Update on Surgical Risk Assessment and Perioperative Management in Cirrhosis: Expert Review.

Authors:  Patrick G Northup; Lawrence S Friedman; Patrick S Kamath
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-28       Impact factor: 11.382

4.  Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons.

Authors:  Karl Y Bilimoria; Yaoming Liu; Jennifer L Paruch; Lynn Zhou; Thomas E Kmiecik; Clifford Y Ko; Mark E Cohen
Journal:  J Am Coll Surg       Date:  2013-09-18       Impact factor: 6.113

Review 5.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.

Authors:  Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler
Journal:  Gastroenterology       Date:  2018-10-10       Impact factor: 22.682

Review 6.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

7.  Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis.

Authors:  Nadim Mahmud; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Hepatology       Date:  2019-03-20       Impact factor: 17.425

8.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

Review 9.  Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.

Authors:  Annalisa Berzigotti; Maria Reig; Juan G Abraldes; Jaime Bosch; Jordi Bruix
Journal:  Hepatology       Date:  2015-01-05       Impact factor: 17.425

10.  Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study.

Authors:  Nadim Mahmud; Rebecca A Hubbard; David E Kaplan; Marina Serper
Journal:  Gastroenterology       Date:  2020-05-06       Impact factor: 33.883

View more
  18 in total

Review 1.  Perioperative management of patients with liver disease.

Authors:  N Gilbert-Kawai; B Hogan; Z Milan
Journal:  BJA Educ       Date:  2022-01-31

Review 2.  Surgical Risk Assessment in Patients with Chronic Liver Diseases.

Authors:  Shekhar S Jadaun; Sanjiv Saigal
Journal:  J Clin Exp Hepatol       Date:  2022-03-23

Review 3.  Bariatric Surgery in NAFLD.

Authors:  Mahak Chauhan; Kuldeep Singh; Paul J Thuluvath
Journal:  Dig Dis Sci       Date:  2022-01-04       Impact factor: 3.199

Review 4.  Value of Liver Function Tests in Cirrhosis.

Authors:  Praveen Sharma
Journal:  J Clin Exp Hepatol       Date:  2021-11-14

5.  Frailty Is a Risk Factor for Postoperative Mortality in Patients With Cirrhosis Undergoing Diverse Major Surgeries.

Authors:  Nadim Mahmud; David E Kaplan; Tamar H Taddei; David S Goldberg
Journal:  Liver Transpl       Date:  2021-02-15       Impact factor: 5.799

Review 6.  Best Practices in Large Database Clinical Epidemiology Research in Hepatology: Barriers and Opportunities.

Authors:  Nadim Mahmud; David S Goldberg; Therese Bittermann
Journal:  Liver Transpl       Date:  2021-08-07       Impact factor: 5.799

7.  External Validation of the VOCAL-Penn Cirrhosis Surgical Risk Score in 2 Large, Independent Health Systems.

Authors:  Nadim Mahmud; Zachary Fricker; Sarjukumar Panchal; James D Lewis; David S Goldberg; David E Kaplan
Journal:  Liver Transpl       Date:  2021-07       Impact factor: 6.112

8.  Accurate long-term prediction of death for patients with cirrhosis.

Authors:  David Goldberg; Alejandro Mantero; David Kaplan; Cindy Delgado; Binu John; Nadine Nuchovich; Ezekiel Emanuel; Peter P Reese
Journal:  Hepatology       Date:  2022-04-01       Impact factor: 17.298

9.  Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.

Authors:  Sarah A Nisly; Alexandra E Mihm; Chris Gillette; Kyle A Davis; Janine Tillett
Journal:  J Thromb Thrombolysis       Date:  2021-03-16       Impact factor: 2.300

10.  Risk Prediction Models for Postoperative Decompensation and Infection in Patients With Cirrhosis: A Veterans Affairs Cohort Study.

Authors:  Nadim Mahmud; Zachary Fricker; James D Lewis; Tamar H Taddei; David S Goldberg; David E Kaplan
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-08       Impact factor: 13.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.